The Science of Wellness
Understanding the Endocannabinoid System
Your body has a built-in regulatory network designed to keep everything in balance. Understanding how it works — and how CBD supports it — changes everything about how you think about natural wellness.
Your Endocannabinoid System
The Foundation
What Is the Endocannabinoid System?
Discovered in the late 1980s, the Endocannabinoid System (ECS) is one of the most important regulatory networks in the human body. It influences everything from how you feel discomfort to how well you sleep — and it's been operating quietly in your body your entire life.
Homeostasis
The ECS acts as your body's master regulator, constantly working to maintain internal balance across all major systems — temperature, mood, sleep, appetite, and discomfort response.
Receptor Network
CB1 and CB2 receptors are distributed throughout your brain, nervous system, and immune tissue, forming a communication network that responds to both internal and external signals.
Endocannabinoids
Your body naturally produces its own cannabinoids — anandamide and 2-AG — which bind to ECS receptors to regulate everything from discomfort signaling to emotional balance.
The Receptor Network
Two Types of Receptors — One Unified System
The ECS operates through two primary receptor types: CB1 and CB2. Together, they form a communication network that spans your entire body — from your brain to your immune cells.
- CB1 receptors are concentrated in the brain and central nervous system
- CB2 receptors are found throughout the immune system and peripheral tissues
- Both receptor types respond to endocannabinoids your body produces naturally
- Phytocannabinoids like CBD can also interact with this receptor network
Natural Production
Your Body Makes Its Own Cannabinoids
Long before anyone discovered CBD, your body was already producing endocannabinoids — natural compounds that bind to the same receptors. Anandamide (named after the Sanskrit word for bliss) and 2-AG are the two most studied.
- Anandamide is produced on demand in response to exercise, stress, and discomfort
- 2-AG is the most abundant endocannabinoid and plays a key role in immune regulation
- Both are broken down by enzymes after they've done their job
- Deficiencies in endocannabinoid production may contribute to chronic discomfort
The Mechanism
How the ECS Works
The ECS operates through a precise three-step process: a signal is produced, a receptor is activated, and a response is generated. This retrograde signaling system is unlike any other in the body — and understanding it reveals why CBD works the way it does.
Signal Produced
When the body detects an imbalance — discomfort, stress, or disrupted sleep — it produces endocannabinoids on demand at the precise site that needs attention.
Receptor Activated
Endocannabinoids travel backward across synapses and bind to CB1 or CB2 receptors, triggering a specific cellular response tailored to the type of imbalance detected.
Balance Restored
Once the receptor is activated, the appropriate response is generated — reduced discomfort signaling, calmer immune activity, or improved sleep regulation — restoring homeostasis.
The CBD Connection
How CBD Supports Your Endocannabinoid System
CBD (cannabidiol) is a phytocannabinoid — a plant-derived compound that interacts with your body's existing ECS. Unlike THC, CBD doesn't directly bind to CB1 or CB2 receptors. Instead, it works as a modulator, helping your ECS function more efficiently by slowing the breakdown of your natural endocannabinoids.
How CBD Interacts with Your ECS
- CBD inhibits FAAH, the enzyme that breaks down anandamide
- Increased anandamide levels support mood and discomfort response
- CBD modulates CB2 receptor activity in peripheral tissues
- Topical application targets local ECS receptors directly at the site
Why Topical CBD Works With Your ECS
Targeted Localized Support
Topical CBD interacts directly with ECS receptors in the skin and underlying tissue, delivering localized support without systemic effects — right where you need it.
Fast-Acting Absorption
Topical cannabinoids bypass the digestive system entirely, allowing for rapid absorption through the skin's CB2-rich layers for quicker localized response.
The Entourage Effect
Full spectrum formulations include multiple cannabinoids and terpenes that work synergistically with your ECS, amplifying the overall effect beyond CBD alone.
Kannaco Formulated for Your ECS
Our topicals are formulated to work with your ECS — not around it.
Every Kannaco product is third-party tested and formulated with clinician input to support your endocannabinoid system where it matters most.
Research & Evidence
The Science Behind the Endocannabinoid System
ECS research spans more than three decades and thousands of peer-reviewed studies. Here are the key milestones that shaped our understanding of this remarkable system — and why it matters for your wellness today.
First Cannabinoid Receptor Discovered
Dr. Allyn Howlett and William Devane identified the first cannabinoid receptor (CB1) in the rat brain, establishing the biological basis for how cannabinoids affect the nervous system.
Source: Howlett et al., Molecular Pharmacology, 1988Anandamide — The Body's Own Cannabinoid
Researchers at Hebrew University discovered anandamide, the first endocannabinoid — a naturally occurring compound produced by the human body that binds to the same receptors as THC.
Source: Devane et al., Science, 1992CB2 Receptor Identified
The second major cannabinoid receptor, CB2, was discovered in the immune system. This finding revealed that the ECS plays a significant role in immune regulation and peripheral tissue response.
Source: Munro et al., Nature, 19932-AG: The Most Abundant Endocannabinoid
2-arachidonoylglycerol (2-AG) was identified as the most abundant endocannabinoid in the body, with full agonist activity at both CB1 and CB2 receptors — playing a key role in immune and neurological regulation.
Source: Mechoulam et al., Biochemical Pharmacology, 1995Raphael Mechoulam Names the ECS
The Israeli chemist who first isolated THC in 1964 formally characterized the endocannabinoid system as a unified regulatory network, coining the term and establishing its role in maintaining homeostasis.
Source: Mechoulam & Ben-Shabat, European Journal of Biochemistry, 1999U.S. Government Patents Cannabinoids as Neuroprotectants
The U.S. Department of Health and Human Services was granted Patent #6,630,507 for cannabinoids as antioxidants and neuroprotectants, acknowledging their therapeutic potential.
Source: U.S. Patent 6,630,507, 2003ECS Receptors Found in Human Skin
Researchers confirmed the presence of both CB1 and CB2 receptors throughout human skin — in keratinocytes, hair follicles, sebaceous glands, and sensory nerve fibers — validating the mechanism for topical cannabinoid activity.
Source: Bíró et al., Trends in Pharmacological Sciences, 2009Clinical Endocannabinoid Deficiency Recognized
Dr. Ethan Russo proposed and documented Clinical Endocannabinoid Deficiency (CECD) as a condition where insufficient ECS tone may contribute to chronic discomfort, sleep disruption, and mood challenges.
Source: Russo, Cannabis and Cannabinoid Research, 2016Common Questions
Frequently Asked Questions About the ECS
Everything you've wondered about the endocannabinoid system, CBD, and how they work together — answered clearly.
The endocannabinoid system (ECS) is a complex cell-signaling network present in all vertebrate animals. It was discovered in the early 1990s and consists of three core components: endocannabinoids (naturally produced by your body), receptors (CB1 and CB2), and enzymes that break down endocannabinoids after they've done their job.
The ECS plays a central role in maintaining homeostasis — the body's ability to regulate and balance key functions including sleep, mood, discomfort response, appetite, and immune activity.
CB1 receptors are primarily found in the brain and central nervous system. They influence mood, memory, discomfort perception, appetite, and motor function. CB1 receptors are the most abundant G-protein-coupled receptors in the brain.
CB2 receptors are concentrated in the immune system and peripheral tissues, including the skin, gut, and spleen. They play a key role in modulating immune responses and peripheral discomfort signaling. Importantly, CB2 receptors are also found throughout the layers of human skin — which is why topical CBD can be so effective.
Yes — your body produces its own cannabinoids, called endocannabinoids. The two most studied are:
Anandamide (AEA) — often called the 'bliss molecule,' anandamide is produced on demand in response to exercise, stress, and discomfort. It binds to both CB1 and CB2 receptors and plays a role in mood regulation, memory, and discomfort response.
2-Arachidonoylglycerol (2-AG) — the most abundant endocannabinoid in the body, 2-AG is a full agonist at both CB1 and CB2 receptors and is particularly important in immune regulation and neurological function.
Unlike hormones, endocannabinoids are produced on demand and broken down quickly by enzymes after use.
CBD (cannabidiol) is a phytocannabinoid — a plant-derived compound that interacts with your body's existing ECS. Unlike THC, CBD does not directly bind to CB1 or CB2 receptors in a way that causes psychoactive effects.
Instead, CBD works primarily by inhibiting FAAH — the enzyme responsible for breaking down anandamide. By slowing anandamide's breakdown, CBD effectively increases its availability and extends its beneficial effects. CBD also modulates CB2 receptor activity and interacts with other receptor systems including TRPV1 (which influences discomfort and temperature sensation) and serotonin receptors.
Topical CBD interacts with the ECS in a fundamentally different way than oral CBD. When applied to the skin, CBD engages directly with the CB1 and CB2 receptors found in the skin's layers — including keratinocytes, sensory nerve fibers, and immune cells — without entering the bloodstream in significant amounts.
This means topical CBD provides localized support at the site of application without systemic effects. For people who want targeted support for a specific area — a knee, shoulder, or lower back — topical application is often the most direct and efficient approach.
Oral CBD, by contrast, must pass through the digestive system and liver before reaching the bloodstream, which reduces bioavailability and delays onset.
The entourage effect refers to the synergistic interaction between multiple cannabinoids, terpenes, and other compounds found in full spectrum hemp extract. The theory, first proposed by Israeli researcher Raphael Mechoulam, suggests that these compounds work better together than any single compound in isolation.
In practical terms, a full spectrum CBD product — which contains CBD alongside minor cannabinoids like CBG, CBN, and CBC, plus terpenes — may produce a more comprehensive ECS response than a CBD isolate product. This is why KannaCo's Cooling Cream uses a full spectrum formulation, while the Pro Cream and Pro Roll-On use a broad spectrum isolate approach for those who prefer 0.0% THC.
Yes. Dr. Ethan Russo, a leading cannabinoid researcher, proposed the concept of Clinical Endocannabinoid Deficiency (CECD) — the idea that insufficient ECS tone may contribute to a range of chronic conditions including fibromyalgia, migraines, and irritable bowel syndrome.
Just as the body can become deficient in other signaling molecules (like serotonin or dopamine), the ECS can become dysregulated. Factors that may contribute to ECS deficiency include chronic stress, poor sleep, sedentary lifestyle, and aging. Supporting the ECS through lifestyle, exercise, and phytocannabinoids like CBD may help restore balance.
CBD is non-psychoactive — it does not produce the 'high' associated with THC. The World Health Organization (WHO) has stated that CBD exhibits no potential for abuse or dependence and has a good safety profile.
KannaCo's Pro Cream and Pro Roll-On contain 0.0% THC (CBD isolate formulations), making them appropriate for anyone concerned about THC exposure, including those subject to drug testing. The Cooling Cream contains less than 0.3% THC (the federally legal threshold) as part of its full spectrum formulation.
As with any wellness product, it's always a good idea to consult your healthcare provider before starting CBD, especially if you take prescription medications.
Most people who use topical CBD report feeling effects within 15 to 45 minutes of application. The onset depends on several factors including the concentration of CBD, the carrier oils used (which affect skin penetration), the area of application, and individual skin characteristics.
For consistent results, we recommend applying KannaCo topicals to clean, dry skin and massaging gently until absorbed. Many users report that effects become more pronounced and consistent with regular daily use over the first 1–2 weeks, as the local ECS receptors become more consistently engaged.
Every KannaCo product is third-party tested by SC Labs — an independent, ISO-accredited laboratory — and a Certificate of Analysis (COA) is available for every batch. The COA confirms:
Potency: Exact CBD, CBG, and other cannabinoid concentrations match label claims. Purity: Products are tested for heavy metals, pesticides, residual solvents, and microbial contaminants. THC compliance: Pro Cream and Pro Roll-On are confirmed at 0.0% THC; Cooling Cream is confirmed at less than 0.3% THC.
KannaCo is also LegitScript certified — a rigorous compliance certification that verifies legal operation and product transparency. You can request a COA for any product batch directly through our website.
Ready to Support Your ECS?
KannaCo's practitioner-formulated topicals are designed to work with your endocannabinoid system — third-party tested, clinician-trusted, and backed by a 60-day guarantee.
These statements have not been evaluated by the Food and Drug Administration. Kannaco products are not intended to diagnose, treat, cure, or prevent any disease. The information on this page is for educational purposes only.
